Skip to Content

What's New

Class Action Involving Cancer Drug Monopoly Pursued to Resolution

Lash & Goldberg LLP served as co-counsel for its named plaintiff client in this federal antitrust class action against Bristol-Myers alleging the unlawful monopolization of the national market for paclitaxel, a cancer drug sold under the brand name Taxol.

The antitrust scheme included Bristol-Myers’ alleged conduct to block generic competition in the United States.  The United States District Court for the District of Columbia approved a settlement in favor of the class of direct purchasers in the amount of $65,815,000.  The litigation and settlement gave rise to other subsequent actions brought by various State Attorney Generals’ offices and the Federal Trade Commission.